Market News AIOpen the app

ImmunityBio's stock went up on Thursday after news about its cancer treatment approval.

TrialRead the original at Benzinga
Good for IBRX

The FDA added papillary-only bladder cancer to ANKTIVA’s approved use, opening treatment to the largest group of these patients. The decision used earlier results from another group, not a new papillary-only trial, but the broader approval favors ImmunityBio.

IBRX · ImmunityBio Inc.

AI read · Good for IBRX

The AI's read

This gives ImmunityBio access to a much larger group of bladder cancer patients. The FDA relied on earlier results in patients with carcinoma in situ, not a new trial in papillary-only patients. Still, papillary disease makes up most cases in this bladder cancer group, and ANKTIVA is now approved for both groups.

Get alerts for IBRX

Follow ImmunityBio Inc. (IBRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IBRX
Free on the App Store and Google Play, or on the web.